TheraQuest Biosciences, LLC. To Present Local Anesthetic Patch Data At Upcoming Rodman & Renshaw 8th Annual Healthcare Conference

BLUE BELL, Pa., Oct. 26 /PRNewswire/ -- TheraQuest Biosciences, a development-stage pain management company, today announced that it will present a corporate overview at the upcoming Rodman & Renshaw 8th Annual Healthcare Conference on Tuesday, November 7, 2006 at 9:55 A.M.

The presentation will include data on TQ-1019, a proprietary local anesthetic patch for the treatment of painful diabetic neuropathy and postherpetic neuralgia. A prototype formulation has been successfully developed. GMP manufacturing and Phase I safety and tolerability studies are scheduled for 2007.

Najib Babul, PharmD, President and Chief Executive Officer, said, “We expect TQ-1019 to be used alone and in combination with oral therapies for neuropathic pain. We believe it has several advantages over currently available topical therapies. It will compete in the same market segment as Lidoderm(TM) Patch, which has a 2006 sales forecast of approximately $900 million. We are seeking a partner with commercialization capabilities to co-develop the product to facilitate a 2009 NDA filing.”

Additional products to be reviewed during the presentation are: * TQ-1011 is a proprietary injectable formulation of ketoprofen for the treatment of moderate to severe post-surgical pain. * TQ-1015 is Broad Spectrum Analgesic(TM) developed as a once-a-day sustained release strong opioid in a proprietary abuse-deterrent drug delivery system. * TQ-1017 is a proprietary abuse-deterrent, once-a-day, sustained release tramadol for the treatment of neuropathic pain, developed using TheraQuest’s Secure Release (SECUREL(TM)) technology.

A live webcast may be viewed at http://www.wsw.com/webcast/rrshq10/theraquest/. A replay will be available for 90 days following the presentation.

About TheraQuest

TheraQuest Biosciences, LLC is a private, development-stage pain management company building a diversified portfolio of pharmaceutical products to address a critical area of unmet medical need. Despite their limitations, current treatments for acute and chronic pain yield worldwide sales in excess of $30 billion. The TheraQuest team has contributed to the development of numerous analgesics approved in the U.S. over the past 20 years. TheraQuest’s strategy is to use its expertise to identify, develop and commercialize product candidates with strong market potential that have lower development costs and reduced regulatory risk than new chemical entities. TheraQuest is headquartered in Blue Bell, Pennsylvania.

http://www.theraquestinc.com

TheraQuest Biosciences, LLC

CONTACT: Najib Babul, PharmD, CEO, TheraQuest Biosciences, LLC,+1-610-272-2071, inquiry@theraquestinc.com

MORE ON THIS TOPIC